QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the expansion of its sample technologies portfolio with the
introduction of two new products aimed at supporting researchers in
managing diverse materials such as bone, tissue and soil
samples:
-
The TissueLyser III, a high-throughput instrument for enhanced and
versatile disruption of a range of biological samples containing
nucleic acids (DNA and RNA).
-
The RNeasy PowerMax Soil Pro Kit, designed for isolating
high-purity RNA from challenging soil samples rich in PCR
inhibitors using QIAGEN’s advanced Inhibitor Removal
Technology.
“The introduction of the TissueLyser III and the
RNeasy PowerMax Soil Pro Kit are further milestones in QIAGEN
continuing to enhance our best-in-class sample technologies
portfolio. These two products are designed to better serve the
unique needs of researchers working with difficult samples and
enable a higher level of efficiency and accuracy in their work,”
said Nitin Sood, Senior Vice President and Head of the Life
Sciences Business Area at QIAGEN.
The TissueLyser III is a well-suited choice for
laboratories seeking efficient sample disruption and high‑quality
DNA and RNA purification, even from difficult-to-lyse samples such
as bones or tissues. It ensures representative and reproducible
results across various research fields, including microbiome,
environmental and human biomedical research, forensic analysis and
cancer research.
Building on the trusted technology of its
prior-generation instrument, which has been cited in over 14,000
scientific publications, the TissueLyser III offers enhanced
capabilities for efficient sample disruption – a critical aspect of
nucleic acid purification procedures. It provides a convenient,
secure process for up to 192 samples as well as large samples of up
to 50 mL [1]. Featuring a touchscreen and rotary knob, the
TissueLyser III ensures ease of use through seven pre-programmed,
as well as five customizable protocols and program cycles.
The TissueLyser III can be used to disrupt
biological samples – such as animal and plant tissues, bacteria and
yeast – through high-speed shaking in tubes or 96-well plates with
stainless zirconium, ceramic, stainless steel or glass beads.
The launch of TissueLyser III demonstrates
QIAGEN’s steadfast commitment to consistently enhancing its
automated solutions for sample preparation and analysis. It
complements the QIAGEN portfolio of high-throughput instruments,
which include QIAcube HT, QIAxcel Connect and QIAsymphony.
The TissueLyser III is compatible with many
QIAGEN kits – including the new RNeasy PowerMax Soil Pro Kit. This
kit is specifically designed for challenging soil samples,
particularly those rich in PCR inhibitors such as compost,
sediment, and manure. Equipped with larger 50 mL bead-beating
tubes, it can handle soil samples of up to 15 grams.
Using QIAGEN’s advanced patent-pending Inhibitor
Removal Technology (IRT) and efficient bead beating and lysis
chemistry, the kit delivers high-yield, high-purity RNA ready for
downstream applications such as real-time quantitative RT-PCR,
digital PCR and next-generation sequencing. Compared to its
predecessor, the RNeasy PowerSoil Total RNA Kit, the streamlined
workflow of the new kit reduces processing time by 60%, enabling
faster discoveries and advancements in the understanding of
microbial ecosystems.
More information on the TissueLyser III is available here:
https://www.qiagen.com/TLIII
More information on the RNeasy PowerMax Soil Pro
Kit is available
here:https://www.qiagen.com/de/products/discovery-and-translational-research/dna-rna-purification/rna-purification/microbial-rna/rneasy-powermax-soil-pro-kit
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
September 30, 2023, QIAGEN employed more than 6,000 people in
over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
[1] Available in Q1 2024.
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024